Igor Spivak1, Anne Rix1, Georg Schmitz2, Stanley Fokong1, Olga Iranzo3,4, Wiltrud Lederle1, Fabian Kiessling5,6. 1. Department of Experimental Molecular Imaging, Medical Faculty, RWTH Aachen University, Aachen, Germany. 2. Institute of Medical Engineering, Ruhr-University Bochum, Bochum, Germany. 3. Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal. 4. Aix Marseille Université, Centrale Marseille, CNRS, iSm2 UMR 7313, 13397, Marseille, France. 5. Department of Experimental Molecular Imaging, Medical Faculty, RWTH Aachen University, Aachen, Germany. fkiessling@ukaachen.de. 6. Institute for Experimental Molecular Imaging, RWTH Aachen University, Pauwelsstrasse 30, 52074, Aachen, Germany. fkiessling@ukaachen.de.
Abstract
PURPOSE: Our objective was to determine the lowest diagnostically effective dose for E-selectin-targeted poly n-butyl cyanoacrylate (PBCA)-shelled microbubbles and to apply it to monitor antiangiogenic therapy effects. PROCEDURES: PBCA-shelled microbubbles (MBs) coupled to an E-selectin-specific peptide were applied in mice carrying MLS or A431 carcinoma xenografts scaling down the MB dosage to the lowest level where binding could be examined with a 18-MHz small animal ultrasound transducer. Differences in E-selectin expression in the two carcinoma xenografts were confirmed by enzyme-linked immunosorbent assay (ELISA). In addition, MLS tumor-bearing mice under antiangiogenic therapy were monitored using E-selectin-targeted MBs at the lowest applicable dose. Therapy effects on tumor vascularization were verified by immunohistological analyses. RESULTS: The minimally required dosage was 7 × 10(7) MBs/kg body weight. This dosage was sufficient to enable E-selectin detection in high E-selectin-expressing MLS tumors, while low E-selectin-expressing A431 tumors required almost 2.5-fold higher doses. At the dose of 7 × 10(7) MBs/kg body weight, a decrease in E-selectin MB binding under antiangiogenic therapy could be assessed (being significant after 3 days of treatment; p < 0.0001), which was in line with the significant drop in E-selectin-positive area fractions that was found histologically (p < 0.05). CONCLUSIONS: Molecular ultrasound imaging with our E-selectin-targeted MB and therapy monitoring was possible down to a dose of 7 × 10(7) MBs/kg body weight (equates to 66 μg PBCA/kg and 4.6 mg PBCA/70 kg). Improvements in choice of targets, MB composition, and other MB detection methods may improve sensitivity and lead to reliable detection results of clinically transferrable MBs at even lower dosage levels.
PURPOSE: Our objective was to determine the lowest diagnostically effective dose for E-selectin-targeted poly n-butyl cyanoacrylate (PBCA)-shelled microbubbles and to apply it to monitor antiangiogenic therapy effects. PROCEDURES: PBCA-shelled microbubbles (MBs) coupled to an E-selectin-specific peptide were applied in mice carrying MLS or A431 carcinoma xenografts scaling down the MB dosage to the lowest level where binding could be examined with a 18-MHz small animal ultrasound transducer. Differences in E-selectin expression in the two carcinoma xenografts were confirmed by enzyme-linked immunosorbent assay (ELISA). In addition, MLS tumor-bearing mice under antiangiogenic therapy were monitored using E-selectin-targeted MBs at the lowest applicable dose. Therapy effects on tumor vascularization were verified by immunohistological analyses. RESULTS: The minimally required dosage was 7 × 10(7) MBs/kg body weight. This dosage was sufficient to enable E-selectin detection in high E-selectin-expressing MLS tumors, while low E-selectin-expressing A431 tumors required almost 2.5-fold higher doses. At the dose of 7 × 10(7) MBs/kg body weight, a decrease in E-selectin MB binding under antiangiogenic therapy could be assessed (being significant after 3 days of treatment; p < 0.0001), which was in line with the significant drop in E-selectin-positive area fractions that was found histologically (p < 0.05). CONCLUSIONS: Molecular ultrasound imaging with our E-selectin-targeted MB and therapy monitoring was possible down to a dose of 7 × 10(7) MBs/kg body weight (equates to 66 μg PBCA/kg and 4.6 mg PBCA/70 kg). Improvements in choice of targets, MB composition, and other MB detection methods may improve sensitivity and lead to reliable detection results of clinically transferrable MBs at even lower dosage levels.
Authors: Huaijun Wang; Stephen A Felt; Steven Machtaler; Ismayil Guracar; Richard Luong; Thierry Bettinger; Lu Tian; Amelie M Lutz; Jürgen K Willmann Journal: Radiology Date: 2015-05-12 Impact factor: 11.105
Authors: Beat A Kaufmann; John M Sanders; Christopher Davis; Aris Xie; Patrick Aldred; Ian J Sarembock; Jonathan R Lindner Journal: Circulation Date: 2007-06-25 Impact factor: 29.690
Authors: Shiying Wang; Elizabeth B Herbst; F William Mauldin; Galina B Diakova; Alexander L Klibanov; John A Hossack Journal: Invest Radiol Date: 2016-12 Impact factor: 6.016
Authors: Samantha M Fix; A Gloria Nyankima; Morgan D McSweeney; James K Tsuruta; Samuel K Lai; Paul A Dayton Journal: Ultrasound Med Biol Date: 2018-03-27 Impact factor: 2.998
Authors: Patrick Koczera; Lia Appold; Yang Shi; Mengjiao Liu; Anshuman Dasgupta; Vertika Pathak; Tarun Ojha; Stanley Fokong; Zhuojun Wu; Marc van Zandvoort; Olga Iranzo; Alexander J C Kuehne; Andrij Pich; Fabian Kiessling; Twan Lammers Journal: J Control Release Date: 2017-03-06 Impact factor: 9.776